Palisade Asset Management LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 10.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 19,338 shares of the biopharmaceutical company’s stock after selling 2,348 shares during the quarter. Palisade Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $992,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of BMY. OFI Invest Asset Management bought a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $25,000. Milestone Investment Advisors LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $27,000. Blue Bell Private Wealth Management LLC boosted its stake in Bristol-Myers Squibb by 61.5% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 200 shares during the period. Turtle Creek Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 4th quarter worth approximately $40,000. Finally, Wetzel Investment Advisors Inc. bought a new position in Bristol-Myers Squibb in the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol-Myers Squibb Stock Up 0.3 %
Shares of BMY traded up $0.14 during midday trading on Tuesday, reaching $44.04. 10,924,172 shares of the stock were exchanged, compared to its average volume of 15,784,603. Bristol-Myers Squibb has a 52 week low of $43.33 and a 52 week high of $69.10. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The company’s 50 day moving average is $50.11 and its two-hundred day moving average is $50.48. The company has a market capitalization of $89.27 billion, a P/E ratio of -14.21, a PEG ratio of 14.82 and a beta of 0.45.
Bristol-Myers Squibb Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 5.45%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently -77.42%.
Analysts Set New Price Targets
Several research firms have weighed in on BMY. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. Wells Fargo & Company increased their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Barclays lowered their target price on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. Finally, BMO Capital Markets decreased their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $60.00.
Check Out Our Latest Research Report on BMY
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Bristol-Myers Squibb
- Investing in large cap stocks: Diving into big caps
- Garmin Navigates to New Highs Driven By Wearables Trend
- How to Calculate Stock Profit
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.